BCART Stock Overview
A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biocartis Group NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.29 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.34 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -91.91% |
| 5 Year Change | -94.92% |
| Change since IPO | -97.77% |
Recent News & Updates
Recent updates
Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding
Jun 17
Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report
Feb 27We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt
Mar 03What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?
Jan 27What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation
Dec 06What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?
Sep 01What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jul 28
Shareholder Returns
| BCART | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -1.5% |
| 1Y | 0% | 5.4% | -0.07% |
Return vs Industry: BCART underperformed the Belgian Medical Equipment industry which returned 5.4% over the past year.
Return vs Market: BCART matched the Belgian Market which returned -0.1% over the past year.
Price Volatility
| BCART volatility | |
|---|---|
| BCART Average Weekly Movement | 0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in BE Market | 6.6% |
| 10% least volatile stocks in BE Market | 2.2% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BCART's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 526 | Roger Moody | www.biocartisgroupnv.be |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
Biocartis Group NV Fundamentals Summary
| BCART fundamental statistics | |
|---|---|
| Market cap | €27.24m |
| Earnings (TTM) | -€67.87m |
| Revenue (TTM) | €60.82m |
0.4x
P/S Ratio-0.4x
P/E RatioIs BCART overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCART income statement (TTM) | |
|---|---|
| Revenue | €60.82m |
| Cost of Revenue | €65.51m |
| Gross Profit | -€4.69m |
| Other Expenses | €63.18m |
| Earnings | -€67.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -7.71% |
| Net Profit Margin | -111.58% |
| Debt/Equity Ratio | -257.9% |
How did BCART perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocartis Group NV is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Bardo | Berenberg |
| Hugo Solvet | Bryan Garnier & Co |
| Guy Sips | KBC Securities NV |